Endometriosis, a debilitating chronic inflammatory condition affecting an estimated 10% of reproductive-age women globally, continues to be plagued by a…
Read More
The Rise of Antibody-Drug Conjugates: Precision Oncology’s Evolving Frontier
Antibody-drug conjugates (ADCs) represent a significant leap forward in targeted cancer therapy, a sophisticated class of drugs that marries the…
Read More
Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Bolster Psychiatric and Neurological Pipeline
TOKYO, JAPAN & BOSTON, USA – March 30, 2026 – Otsuka Pharmaceutical Co., Ltd. announced today that its subsidiary, Otsuka…
Read More
MSD’s $6.7 Billion Acquisition of Terns Pharmaceuticals Signals a Bold Strategic Pivot in Oncology to Secure Future Growth
On March 25, Merck & Co. (MSD) announced a significant strategic move, acquiring Terns Pharmaceuticals for an estimated $6.7 billion…
Read More
The Crucial Role of Payload Linker Innovation in the Rapidly Expanding Antibody-Drug Conjugate Market
Combining the targeted precision of monoclonal antibodies with the potent destructive power of cytotoxic payloads, Antibody-Drug Conjugates (ADCs) represent a…
Read More
Novo Nordisk Secures FDA Approval for Awiqli, a Once-Weekly Basal Insulin for Adults with Type 2 Diabetes
The United States Food and Drug Administration (FDA) has granted approval to Novo Nordisk for Awiqli (insulin icodec-abae) injection 700…
Read More
Simulations Plus Forges Strategic Alliances to Pioneer AI-Driven Drug Development
Simulations Plus, a leading provider of advanced modeling and simulation software for drug discovery and development, has announced the establishment…
Read More
Novartis to Acquire Excellergy for Up to $2 Billion to Bolster Next-Generation Anti-IgE Allergy Pipeline
Novartis has entered into a definitive agreement to acquire Excellergy, a privately held biotechnology company specializing in the development of…
Read More
Darzalex Secures Landmark European Approval for Self-Administration in Multiple Myeloma, Ushering in a New Era of Home-Based Cancer Care
Johnson & Johnson’s (J&J) groundbreaking cancer immunotherapy, Darzalex (daratumumab), has achieved a pivotal milestone in its European market penetration with…
Read More
Europe’s Biopharmaceutical Competitiveness and Commercial Strategies Under Scrutiny at BIO Europe Spring
Lisbon, Portugal – As the vibrant city of Lisbon recently concluded its tenure as host for the annual BIO Europe…
Read More
